Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Two-part, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of SENS-401 in Subjects With Severe or Profound Sudden Sensorineural Hearing Loss

Trial Profile

A Two-part, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of SENS-401 in Subjects With Severe or Profound Sudden Sensorineural Hearing Loss

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 12 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Arazasetron (Primary)
  • Indications Sensorineural hearing loss
  • Focus Registrational; Therapeutic Use
  • Acronyms AUDIBLE-S
  • Sponsors Sensorion
  • Most Recent Events

    • 12 Jul 2019 According to a Sensorion media release, top line data from this trial is expected in mid-2020.
    • 12 Jun 2019 According to a Sensorion media release, the phase 2 part is underway and interim read out results should be available by the end of the year (2019).
    • 12 Jun 2019 According to a Sensorion media release, the funds from Invus Public Equities LP and Sofinnova Crossover will be used to fund the clinical phase 2 programs for SENS-401.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top